Sophie Matis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sophie Matis has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ramon Landin-Romero
Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney Sydney New South Wales Australia
4 shared publications - Olivier Piguet
Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia
2 shared publications - Sheryl L. Foster
Discipline of Medical Imaging Science Sydney School of Health Sciences Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
2 shared publications Ana Rita Barreiros
1 shared publication- Ana Rita Barreiros
Brain Dynamics Centre, Westmead Institute for Medical Research, Sydney, Australia
1 shared publication Anthony Harris
1 shared publication
Latest Publications
- Open Access
- 18 May 2025
- Published by Elsevier in Journal of Affective Disorders Reports
- Vol. 21
Amygdala subregional functional connectivity in treatment-resistant depression
- 18 May 2025
- Published by Elsevier in Journal of Affective Disorders Reports
- Vol. 21
Open AccessAmygdala subregional functional connectivity in treatment-resistant depression
- Open Access
Reduced plasma hexosylceramides in frontotemporal dementia are a biomarker of white matter integrity
INTRODUCTION: Blood biomarkers are needed to facilitate new therapeutic trials and improve management of behavioural variant frontotemporal dementia (bvFTD). Since altered white matter integrity is characteristic of bvFTD, this study aimed to determine if plasma levels of myelin-enriched glycolipids are altered in bvFTD and correlate with white matter integrity. METHODS: Nineteen glycolipids were quantified in bvFTD (n=31) and control (n=26) plasma samples. White matter integrity was assessed using MRI-derived fibre tract density and cross-section (FDC). RESULTS: Eleven lipids were significantly lower in bvFTD compared to control subjects, seven were inversely correlated with disease duration, and twelve were positively correlated with cognitive performance, with C22:0 hexosylceramide most strongly correlated. FDC was lower in frontotemporal white matter tracts of bvFTD compared to control subjects, and plasma C22:0 hexosylceramide was significantly correlated with FDC in these tracts. DISCUSSION: Circulating glycolipids may be a valuable biomarker of myelin integrity and disease progression in FTD.
Open AccessReduced plasma hexosylceramides in frontotemporal dementia are a biomarker of white matter integrity
INTRODUCTION: Blood biomarkers are needed to facilitate new therapeutic trials and improve management of behavioural variant frontotemporal dementia (bvFTD). Since altered white matter integrity is characteristic of bvFTD, this study aimed to determine if plasma levels of myelin-enriched glycolipids are altered in bvFTD and correlate with white matter integrity. METHODS: Nineteen glycolipids were quantified in bvFTD (n=31) and control (n=26) plasma samples. White matter integrity was assessed using MRI-derived fibre tract density and cross-section (FDC). RESULTS: Eleven lipids were significantly lower in bvFTD compared to control subjects, seven were inversely correlated with disease duration, and twelve were positively correlated with cognitive performance, with C22:0 hexosylceramide most strongly correlated. FDC was lower in frontotemporal white matter tracts of bvFTD compared to control subjects, and plasma C22:0 hexosylceramide was significantly correlated with FDC in these tracts. DISCUSSION: Circulating glycolipids may be a valuable biomarker of myelin integrity and disease progression in FTD.
- Open Access
Amygdala subregional functional connectivity in Treatment-Resistant Depression
Background: Treatment resistance impacts almost 50% of depression patients, with amygdala dysfunction being widely implicated. The amygdala is a complex amalgamation of subnuclei with diverse functions but fMRI studies have typically focussed on identifying whole rather than subregional amygdala functional connectivity. This study used high resolution 3T fMRI data to investigate subregional alterations that may differentiate treatment-resistant cohorts from healthy individuals and depressed patients who respond to treatment. Methods: Resting-state fMRI data were obtained in 35 participants diagnosed with Treatment-Resistant Depression (TRD), 38 healthy control participants (HC), and 35 treatment-sensitive participants (TSD). Seed-based functional connectivity analyses of the three main subregions bilaterally (laterobasal, centromedial and superficial), as well as the whole amygdala, were performed and comparisons made between groups. Results: We found c onnectivity differences in the right laterobasal amygdala subregion in TRD compared to both groups. TRD patients displayed hypoconnectivity to the right fusiform gyrus relative to HC whereas hyperconnectivity to the left inferior frontal gyrus relative to TSD was identified. No connectivity differences were found for the whole amygdala or any of the other subregions bilaterally. Limitations: Modest sample size and cross-sectional study design are limitations. A causal relationship between functional connectivity alterations and treatment resistance cannot be established. Conclusion: Altered connectivity of the right laterobasal subregion is a distinguishing feature of TRD. These alterations may underlie severe impairments in emotion processing and social functioning that are characteristic of TRD. These results emphasise the need for further investigation of the functional role of the amygdala subregions in depression.
Open AccessAmygdala subregional functional connectivity in Treatment-Resistant Depression
Background: Treatment resistance impacts almost 50% of depression patients, with amygdala dysfunction being widely implicated. The amygdala is a complex amalgamation of subnuclei with diverse functions but fMRI studies have typically focussed on identifying whole rather than subregional amygdala functional connectivity. This study used high resolution 3T fMRI data to investigate subregional alterations that may differentiate treatment-resistant cohorts from healthy individuals and depressed patients who respond to treatment. Methods: Resting-state fMRI data were obtained in 35 participants diagnosed with Treatment-Resistant Depression (TRD), 38 healthy control participants (HC), and 35 treatment-sensitive participants (TSD). Seed-based functional connectivity analyses of the three main subregions bilaterally (laterobasal, centromedial and superficial), as well as the whole amygdala, were performed and comparisons made between groups. Results: We found c onnectivity differences in the right laterobasal amygdala subregion in TRD compared to both groups. TRD patients displayed hypoconnectivity to the right fusiform gyrus relative to HC whereas hyperconnectivity to the left inferior frontal gyrus relative to TSD was identified. No connectivity differences were found for the whole amygdala or any of the other subregions bilaterally. Limitations: Modest sample size and cross-sectional study design are limitations. A causal relationship between functional connectivity alterations and treatment resistance cannot be established. Conclusion: Altered connectivity of the right laterobasal subregion is a distinguishing feature of TRD. These alterations may underlie severe impairments in emotion processing and social functioning that are characteristic of TRD. These results emphasise the need for further investigation of the functional role of the amygdala subregions in depression.